biotech

If you're an experienced biotech investor or a novice - you probrably know and understand MOST biotechs are development stage companies.  This is Wall Street "speak" for they lose money and many of them are in a continual state of scrambling for cash.  When a company has great science but poor cash many times it's an unfortunate "trap" for the investor.  I am publishing some of our firm's research which is an "estimate" of current cash reserves and more importantly - NET CASH, which gives an idea how much the company has after paying off all debt and liabilities.

NOTE: You can download the attached FULL PDF

We upgrade our rating to BUY from HOLD based on our increased conviction for compelling Phase II results for TH-302 in combination with standard chemotherapeutics.

with an orginal PDUFA date 7/30/2009  potential delay to no later then 10/30/2009 (FDA decision could come any time after 7/30 but its unusual for the FDA to go early) Transcept is the result of a reverse merger of Transcept (private company) and Novecea (NOVC) Novacea was bought for the cash and the resulting company is under the radar of most biotech investors as well as Wall Street.  Now you have a company that isn't followed by the street or any biotech analyst which has a drug thats already through all phase 3 tests and is just waiting on FDA decision.   They have a big wad of cash to boot meaning they won't need to do any dillutive financings.  This interesting trade pote

• Product Development - Hypoxic Depth Charge - Threshold Pharmaceuticals has preliminary Phase I/II data showing that its TH-302 hypoxia-activated prodrug (HAP) could kill cells in hypoxic regions of tumors where chemotherapy doesn't reach.
From BioCentury - http://www.biocentury.com
 
By Aaron Bouchie
Senior Writer

Here's an excel spreadsheet with a bunch of bios - I have updated most of the balance sheet info to reflect the lastest 10q avaialble for each of them.